RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$12.99
+3.51% today
Updated 2026-04-29
Market cap
$201.54M
P/E ratio
—
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
—
52W range
$12 – $17
Volume
1.5M
Atrium Therapeutics, Inc. Common Stock (RNA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-17.1%
Last 4 quarters
Revenue YoY growth
-71.1%
Most recent quarter
EPS YoY growth
-98.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.7%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+10.9%
2026-03-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-03 | $-1.59 | -28.2% | $14.91 | $16.54 | +10.9% |
| 2025-11-10 | $-1.27 | -11.4% | $69.84 | $70.70 | +1.2% |
| 2025-08-07 | $-1.21 | -26.5% | $48.26 | $46.29 | -4.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.24 | $-1.59 | -28.2% | $859000.00 | -71.1% |
| 2025-09-30 | $-1.14 | $-1.27 | -11.4% | $12.47M | +434.0% |
| 2025-06-30 | $-0.96 | $-1.21 | -26.5% | $3.85M | +88.1% |
| 2025-03-31 | $-0.88 | $-0.90 | -2.2% | $1.57M | -55.6% |
| 2024-12-31 | $-0.78 | $-0.80 | -2.4% | $2.97M | +35.6% |
| 2024-09-30 | $-0.71 | $-0.65 | +8.5% | $2.34M | -17.1% |
| 2024-06-30 | $-0.79 | $-0.65 | +17.7% | $2.04M | -11.7% |
| 2024-03-31 | $-0.78 | $-0.79 | -1.3% | $3.54M | — |
| 2023-12-31 | $-0.66 | $-0.79 | -19.7% | $2.19M | — |
| 2023-09-30 | $-0.77 | $-0.71 | +7.8% | $2.82M | — |
| 2023-06-30 | $-0.80 | $-0.66 | +17.5% | $2.32M | — |
Frequently asked questions
Has Atrium Therapeutics, Inc. Common Stock beaten earnings estimates?
Atrium Therapeutics, Inc. Common Stock has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -17.1% over the last 4 quarters.
How does RNA stock react to earnings?
RNA stock has moved an average of +2.7% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Atrium Therapeutics, Inc. Common Stock's revenue growth rate?
Atrium Therapeutics, Inc. Common Stock reported year-over-year revenue growth of -71.1% in its most recent quarter, with EPS growing -98.8% year-over-year.